trilaciclib Chemische Eigenschaften,Einsatz,Produktion Methoden

Verwenden

Trilaciclib is indicated to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.

Trademarks

Cosela^TM

Synthese

The synthesis of trilaciclib is as follows:
Intermediate 2 (21.1 g, 70 mmol) and 1-methyl-4-(6-aminopyridin-3-yl)piperazine (13.4 g, 70 mmol) were added to a 100 mL vacuum tube and reacted at 230° C. for 3 h.After the reaction, 300 mL of ethyl acetate was added, washed with water (120 mL) and saturated brine (120 mL) successively, dried with anhydrous sodium sulfate and filtered, the obtained solution was evaporated under reduced pressure to remove the solvent, and the obtained residue was recrystallized with ethanol, 27.5 g of Trilaciclib was obtained with a purity of 99% and a yield of 88%.

Lager

Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years).

trilaciclib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

trilaciclib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Anhui Ruihan Technology Co., Ltd	+8617756083858	daisy@anhuiruihan.com	China	973	58
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32951	60
Shenzhen Nexconn Pharmatechs Ltd	+86-755-89396905 +86-15013857715	admin@nexconn.com	China	10310	58
Jinan Carbotang Biotech Co.,Ltd.	+8615866703830	figo.gao@foxmail.com	China	8497	58
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32070	58
Win-Win chemical CO., Limited	+86-0086-577-64498589 +86-15355981851	sales@win-winchemical.com	China	14349	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6391	58
Nantong HI-FUTURE Biology Co., Ltd.	+undefined18051384581	sales@chemhifuture.com	China	3135	58
TargetMol Chemicals Inc.		support@targetmol.com	United States	38463	58
Shanghai Huici Pharmaceutical Technology Co., LTD	+8618917134367	lixing@pharmahuici.com	China	133	58

1374743-00-6()Verwandte Suche:

---

• 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
• 2'-((5-(4-methylpiperazin-1-yl) yridine-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
• Spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one, 7',8'-dihydro-2'-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]-
• 2'-[4-(4-methylpiperazin-1-yl)anilino]-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
• Trilaciclib (G1T28)
• Trilaciclib
• 2'-((5-(4-Methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one
• trilaciclib impurity
• 1374743-00-6